CEOs past performance predicted failure

Discussion in 'The Medicines Company' started by anonymous, Oct 26, 2017 at 5:58 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    One has to look no further than your CEOs inability to deliver any shareholder value over the long course of his tenure. A few years back a bunch of naive sales people flocked to this company having been sold MDCO would be the next ID powerhouse. A cursory review of past performance and an understanding of the products that would serve as the foundation would have led any knowledgeable person to see this coming a mile away. Many were warned but the promise of pay way above market and far too much for the people they hired apparently blinded common sense.
    The board should have canned Clive years ago and are an appalling example of corporate governance. This company should be dimantled and Clive sent packing.
     

  2. anonymous

    anonymous Guest

    Agreed, Clive has not been able to launch one product with any type of measurable success, his inability to listen to those that have extensive experience has been loud and clear over the last 4-5 product launches. My question is where is the board and why haven’t they displaced Clive as of yet? How do they justify a10% drip in share price over night and not act!!! He had been one of the poorest performing CEO in biotechnology history!! Now all of those that have worked tirelessly over the years to make this company a success will lose of the stock options and shares that they have purchased and been allocated as a part of their compensation, while he continues to profit from selling off the franchises. How much is he going to make from the sale of the ID franchise, while those that have actually performed get CHEATED!! From those equity awards?